Travere Therapeutics, Inc. Common Stock
TVTXStock
$55.28+246.40%52W
Market Cap$5.14B
P/E—
Div yield—
Beta1.02
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)46.94%
Price vs S&P 500 (4W)5.70%
VGM Score60.70
Market Capitalization$5.14B
Earnings Surprise History
Q1 26-0.40est. -0.27
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.24
4.24
4.29
4.29
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TVTXTravere Therapeutics, Inc. Common Stock | F | B | A | $55.28 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Travere Therapeutics is a biopharmaceutical company developing therapies for rare kidney, liver, and metabolic diseases. Its lead candidate, sparsentan, is in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), both rare kidney disorders that can progress to end-stage kidney disease. The company is also advancing pegtibatinase, an investigational enzyme replacement therapy for HCU, a genetic metabolic disorder.